No, HBsAg Testing Alone Is NOT Sufficient Before Rituximab
Testing for HBsAg alone is inadequate before initiating rituximab therapy. You must also test for anti-HBc (hepatitis B core antibody), as patients who are HBsAg-negative but anti-HBc-positive can still experience potentially fatal HBV reactivation. 1, 2, 3
Required Screening Panel
Before starting rituximab, you must obtain:
- HBsAg (hepatitis B surface antigen)
- Anti-HBc (total immunoglobulin or IgG)
- Anti-HBs (antibody to hepatitis B surface antigen) 1, 2
The FDA label for rituximab explicitly states: "Screen all patients for HBV infection by measuring HBsAg and anti-HBc before initiating treatment with RITUXAN" 3. This is not optional—it's a boxed warning requirement.
Why HBsAg Alone Misses Critical Cases
The Problem of Occult HBV Infection
Patients who are HBsAg-negative but anti-HBc-positive represent resolved or occult HBV infection. These patients:
- Still harbor HBV DNA in hepatocytes (detectable in ~10% of cases) 4
- Face substantial reactivation risk with rituximab, a high-risk B-cell depleting agent 1, 2
- Can develop fulminant hepatitis, hepatic failure, and death if reactivation occurs 3
Real-world evidence shows HBV reactivation occurs predominantly in patients who were never properly screened 5. In one case report, a patient with positive anti-HBs (suggesting immunity) still experienced HBV reactivation with rituximab because anti-HBc was positive 6.
The Clinical Reality
Studies demonstrate that:
- Only 46-60% of rituximab patients receive complete HBV screening 7, 5
- When screening is incomplete, reactivation events occur that could have been prevented 5, 8
- HBV reactivation carries 28% liver-related mortality in some cohorts 8
Management Algorithm Based on Screening Results
If HBsAg-Positive (Chronic HBV)
- Start antiviral prophylaxis immediately with high-barrier agents (entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide) 1, 2
- Continue during rituximab therapy plus 12 months after completion 2, 3
- This is non-negotiable for all HBsAg-positive patients receiving rituximab
If HBsAg-Negative but Anti-HBc-Positive (Resolved/Occult HBV)
Rituximab is classified as high-risk for HBV reactivation 1. For anti-CD20 antibody therapy specifically:
- Antiviral prophylaxis is recommended (not just monitoring) 2
- Use entecavir, TDF, or TAF 1, 2
- Continue for at least 12 months after rituximab completion 2
The 2025 AGA guideline classifies B-cell-depleting agents as high-risk (>10% reactivation risk) and strongly recommends prophylaxis over monitoring for this group 1.
If Both HBsAg and Anti-HBc Negative
- No prophylaxis needed
- Patient has no evidence of current or prior HBV infection
Critical Pitfalls to Avoid
Don't assume anti-HBs positivity provides protection: Case reports document reactivation despite positive anti-HBs when anti-HBc is also positive 6
Don't delay cancer therapy for screening results: Obtain screening before or at treatment initiation, but don't postpone rituximab 2
Don't use lamivudine: It has high resistance rates. Use entecavir, TDF, or TAF 1, 2
Don't stop monitoring early: HBV reactivation can occur up to 24 months after rituximab completion 3
Don't screen with HBsAg alone: This misses 100% of occult HBV cases who remain at high risk 1, 2, 3
The Bottom Line
The evidence is unequivocal across multiple high-quality guidelines and the FDA label: HBsAg testing alone is insufficient and potentially dangerous before rituximab therapy. The complete triad (HBsAg, anti-HBc, anti-HBs) is required to identify all patients at risk and prevent potentially fatal HBV reactivation. This is a strong recommendation based on moderate-to-high certainty evidence and regulatory requirements 1, 2, 3.